Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide
- PMID: 1568291
- DOI: 10.1007/BF00684851
Unusual dynamics of killing of cultured Lewis lung cells by the DNA-intercalating antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide
Abstract
The cytotoxicity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (AC; NSC 601,316), a new experimental DNA-intercalating antitumor drug, against a cultured Lewis lung adenocarcinoma cell line was compared with that of the DNA-intercalating antitumor drug amsacrine. In contrast to amsacrine, AC demonstrated self-inhibition of cytotoxicity following short (3-9 h) incubation periods and exponential killing (with a shoulder) after long (24-72 h) periods of incubation. The difference between these drugs was best demonstrated using a constant concentration x time (C x T) exposure (AC, 12 mumol h l-1; amsacrine, 3 mumol h l-1). In contrast to amsacrine, AC was minimally effective over exposure periods of less than or equal to 1 h and maximally effective over intermediate periods (4-6 h). The results suggest the possibility of designing AC administration protocols that maximise the drug's cytotoxicity towards solid tumors, which, because of diffusion barriers, are subjected to longer drug exposures than are well-vascularised tumours.
Similar articles
-
Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II.Eur J Cancer Clin Oncol. 1988 Nov;24(11):1783-90. doi: 10.1016/0277-5379(88)90082-x. Eur J Cancer Clin Oncol. 1988. PMID: 2850193
-
Selectivity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro.Eur J Cancer Clin Oncol. 1989 Feb;25(2):271-7. doi: 10.1016/0277-5379(89)90019-9. Eur J Cancer Clin Oncol. 1989. PMID: 2702982
-
Chemoprotection by 9-aminoacridine derivatives against the cytotoxicity of topoisomerase II-directed drugs.Eur J Cancer Clin Oncol. 1989 Dec;25(12):1695-701. doi: 10.1016/0277-5379(89)90337-4. Eur J Cancer Clin Oncol. 1989. PMID: 2561099
-
Mechanisms of action of DNA intercalating acridine-based drugs: how important are contributions from electron transfer and oxidative stress?Curr Med Chem. 2003 Dec;10(24):2643-9. doi: 10.2174/0929867033456332. Curr Med Chem. 2003. PMID: 14529454 Review.
-
The mechanism of action of mAMSA.Adv Cancer Res. 1985;44:267-93. doi: 10.1016/s0065-230x(08)60029-9. Adv Cancer Res. 1985. PMID: 3898738 Review. No abstract available.
Cited by
-
In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance.Cancer Chemother Pharmacol. 1993;31(5):401-6. doi: 10.1007/BF00686155. Cancer Chemother Pharmacol. 1993. PMID: 8381721
-
The role of topoisomerases and RNA transcription in the action of the antitumour benzonaphthyridine derivative SN 28049.Cancer Chemother Pharmacol. 2008 Oct;62(5):753-62. doi: 10.1007/s00280-007-0660-z. Epub 2008 Jan 3. Cancer Chemother Pharmacol. 2008. PMID: 18175117 Free PMC article.
-
Cytokinetic differences in the action of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin.Cancer Chemother Pharmacol. 1993;32(6):463-70. doi: 10.1007/BF00685891. Cancer Chemother Pharmacol. 1993. PMID: 8258195
-
Tumour profile of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after intraperitoneal administration in the mouse.Cancer Chemother Pharmacol. 1993;32(4):320-2. doi: 10.1007/BF00686179. Cancer Chemother Pharmacol. 1993. PMID: 8324875
-
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.Invest New Drugs. 2003 Aug;21(3):347-52. doi: 10.1023/a:1025476813365. Invest New Drugs. 2003. PMID: 14578683 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical